Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.
2.

Episodic Src activation in uveal melanoma revealed by kinase activity profiling.

Maat W, el Filali M, Dirks-Mulder A, Luyten GP, Gruis NA, Desjardins L, Boender P, Jager MJ, van der Velden PA.

Br J Cancer. 2009 Jul 21;101(2):312-9. doi: 10.1038/sj.bjc.6605172. Epub 2009 Jun 30.

3.

The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.

Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE.

Mol Cancer Ther. 2016 Aug;15(8):1952-63. doi: 10.1158/1535-7163.MCT-15-0702. Epub 2016 May 24.

PMID:
27222538
4.
5.

cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner.

Hecquet C, Lefevre G, Valtink M, Engelmann K, Mascarelli F.

Oncogene. 2002 Sep 5;21(39):6101-12.

6.

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.

Buettner R, Mesa T, Vultur A, Lee F, Jove R.

Mol Cancer Res. 2008 Nov;6(11):1766-74. doi: 10.1158/1541-7786.MCR-08-0169.

7.

Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells.

Calipel A, Mouriaux F, Glotin AL, Malecaze F, Faussat AM, Mascarelli F.

J Biol Chem. 2006 Apr 7;281(14):9238-50. Epub 2006 Feb 1.

8.

Src inhibitors in suppression of papillary thyroid carcinoma growth.

Henderson YC, Toro-Serra R, Chen Y, Ryu J, Frederick MJ, Zhou G, Gallick GE, Lai SY, Clayman GL.

Head Neck. 2014 Mar;36(3):375-84. doi: 10.1002/hed.23316. Epub 2013 Jun 1.

9.

Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.

Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H, Penland S, Arbiser J, Scott G, Zhou T, Bar-Eli M, Bear JE, Der CJ, Kaufmann WK, Rimm DL, Sharpless NE.

Cancer Res. 2007 Feb 15;67(4):1502-12.

10.

The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.

Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.

Invest Ophthalmol Vis Sci. 2010 Jan;51(1):421-9. doi: 10.1167/iovs.09-3974. Epub 2009 Aug 6.

PMID:
19661225
11.
12.

RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas.

Fagiani E, Giardina G, Luzi L, Cesaroni M, Quarto M, Capra M, Germano G, Bono M, Capillo M, Pelicci P, Lanfrancone L.

Cancer Res. 2007 Apr 1;67(7):3064-73.

13.

Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.

Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ, Peng SB.

J Biol Chem. 2012 Aug 10;287(33):28087-98. doi: 10.1074/jbc.M112.377218. Epub 2012 Jun 22.

14.

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

Ferguson J, Arozarena I, Ehrhardt M, Wellbrock C.

Oncogene. 2013 Jan 3;32(1):86-96. doi: 10.1038/onc.2012.25. Epub 2012 Feb 6.

15.

Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.

Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar AP.

Cancer Lett. 2009 Oct 8;283(2):143-51. doi: 10.1016/j.canlet.2009.03.035. Epub 2009 Apr 26.

PMID:
19398150
16.

Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.

Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB.

Mol Cancer Ther. 2010 Aug;9(8):2322-32. doi: 10.1158/1535-7163.MCT-09-1212. Epub 2010 Aug 3.

17.

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.

Eustace AJ, Crown J, Clynes M, O'Donovan N.

J Transl Med. 2008 Sep 29;6:53. doi: 10.1186/1479-5876-6-53.

18.

HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.

deBlacam C, Byrne C, Hughes E, McIlroy M, Bane F, Hill AD, Young LS.

Br J Cancer. 2011 Jun 28;105(1):118-23. doi: 10.1038/bjc.2011.193. Epub 2011 Jun 7.

19.

Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.

Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara K, Fukuoka M, Nishio K, Nakagawa K.

Mol Cancer Ther. 2010 May;9(5):1188-97. doi: 10.1158/1535-7163.MCT-10-0002. Epub 2010 Apr 20.

20.

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Cheung M, Sharma A, Madhunapantula SV, Robertson GP.

Cancer Res. 2008 May 1;68(9):3429-39. doi: 10.1158/0008-5472.CAN-07-5867.

Supplemental Content

Support Center